Haleon recalls some lots of adult cough syrup Robitussin over microbial contamination

Written By :  Ruchika Sharma
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-01-29 04:30 GMT   |   Update On 2024-03-23 11:49 GMT

Haleon is recalling some lots of its adult cough syrup Robitussin because of microbial contamination, the U.S. Food and Drug Administration (FDA) has said.The consumer healthcare company is recalling the cough syrup, sold under the brand name "Robitussin Honey CF Max Day Adult" in 4-ounce and 8-ounce doses, along with its 8-ounce night-time version."The voluntary recall is limited to certain...

Login or Register to read the full article

Haleon is recalling some lots of its adult cough syrup Robitussin because of microbial contamination, the U.S. Food and Drug Administration (FDA) has said.

The consumer healthcare company is recalling the cough syrup, sold under the brand name "Robitussin Honey CF Max Day Adult" in 4-ounce and 8-ounce doses, along with its 8-ounce night-time version.
"The voluntary recall is limited to certain lots of Robitussin Honey CF Max Day Adult and Robitussin Honey CF Max Nighttime Adult manufactured and sold in the U.S. only," a Haleon spokesperson said in an email response.
Using the tainted drugs could potentially cause severe or life-threatening adverse events like fungal infections in patients with compromised immunity, the FDA said in a release on Wednesday.
However, it added Haleon has so far not received any reports of adverse events related to these syrups.
The company, which was spun off from GSK in 2022, is notifying its distributors and customers directly and has provided them with instructions for the return of all the drugs to be recalled, the regulator said.
Read also: GSK raises USD 1.24 billion from latest Haleon stake sale
Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News